Overview

Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Celgene Corporation
Treatments:
Apremilast
Thalidomide